首页 > 市场调查报告书 > 医疗设备

体外诊断癌症液体活检

市场调查报告书

商品编码

1560795

全球乳癌液体活检市场 - 2024 - 2031

Global Breast Cancer Liquid Biopsy Market - 2024 - 2031

出版日期: 2024年09月23日 | 出版商:

DataM Intelligence | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

报告概述

全球乳癌液体切片市场在2023年达到16亿美元，预计2031年将达到79.8亿美元，2024-2031年预测期间复合年增长率为23.2%。

液体活检是对血液、尿液或其他体液样本进行的实验室测试，以寻找肿瘤中的癌细胞或肿瘤细胞释放到人体体液中的小片段 DNA、RNA 或其他分子。液体活检可以随着时间的推移采集多个样本，这可能有助于医生了解肿瘤中正在发生什么样的遗传或分子变化。液体活检可用于帮助早期发现癌症。它也可用于帮助计划治疗或了解治疗效果如何或癌症是否復发。

它由不同的生物基质组成，例如循环肿瘤细胞（CTC）、无细胞核酸、外泌体或肿瘤「教育血小板」。在许多情况下，微流体的使用极大地促进了最近的技术和分子进步，使得纯化和分析液体活检成分的能力取得了巨大进步。

市场动态：

司机

乳癌盛行率增加

乳癌液体活检市场的需求是由多种因素驱动的。乳癌盛行率的上升推动了市场的成长。

此外，人们意识的提高和技术进步将推动对治疗的需求。例如，根据 uicc.org 的数据，乳癌是全球女性中诊断最多的癌症，也是 157 个国家女性中诊断最多的癌症，占癌症病例的四分之一。它是两性中第二常见的癌症，也是女性癌症死亡的主要原因。预计到 2022 年将有 230 万新发乳癌病例，全球诊断出的男女癌症中大约每 9 例就有 1 例是乳癌。 2022 年，估计有 669,418 人死于乳癌，其中大部分死亡发生在资源匮乏的地区。

此外，据breastcancer.org称，大约66%的乳癌病例是在癌症扩散到乳房之外之前最容易治疗的局部阶段被诊断出来的。目前美国有超过四百万女性有乳癌病史。

此外，根据世界卫生组织2023年2月发布的一篇文章，每年有超过230万例乳癌病例，这使其成为成人中最常见的癌症。在 95% 的国家中，乳癌是女性癌症死亡的第一或第二大原因。然而，乳癌的存活率在国家之间和国家内部存在广泛不平等，近 80% 的乳癌和子宫颈癌死亡发生在低收入和中等收入国家。

限制

液体活检相关的高成本、熟练专业人员的短缺以及批准新疗法的严格监管要求等因素预计将阻碍市场。

细分市场分析

全球乳癌液体活检市场根据产品类型、循环生物标记、应用、最终用户和地区进行细分。

循环肿瘤细胞（CTC）部分约占全球乳癌液体切片市场份额的47.9%

预计循环肿瘤细胞细分市场将在预测期内占据最大的市场份额。在这一领域，技术进步以及私人製造商用于研究工作的资金不断增加将推动该市场的发展。

循环肿瘤细胞（CTC）作为液体活检在临床应用和基础癌症研究中具有巨大潜力。液体活检是一种微创技术，可以直接从体液中检测癌症生物标记。在这些生物标记中，CTC、游离 DNA (cfDNA) 和 RNA 提供了对肿瘤遗传景观的动态了解。这种革命性的方法为早期癌症检测、监测疾病进展和客製化个人化治疗策略提供了一个有前景的途径。

CTC 现在被认为是转移过程中的关键参与者。它们的检测和分析为液体活检技术的发展铺平了道路，为传统组织活检提供了微创替代方案。这种创新方法彻底改变了我们对肿瘤动态的理解，实现即时监测并提供对肿瘤异质性、治疗反应和疾病进展的见解。

市场地理分析

北美约占全球乳癌液体切片市场份额的42.8%

预计北美地区将在预测期内占据最大的市场份额。该地区乳癌发病率的上升以及人们意识的提高有助于推动市场发展。

例如，根据 Breastcancer.org 的数据，大约 13%（约八分之一）的美国女性在一生中会罹患侵袭性乳癌。近年来，发病率每年略有增加0.5%。乳癌仍然是美国女性癌症相关死亡的主要原因之一，仅次于肺癌。乳癌是美国女性中继皮肤癌之后最常见的癌症。每年，大约 30% 的女性新诊断癌症是乳癌。目前美国有超过四百万女性有乳癌病史。

此外，2023年6月，Labcorp推出液体切片检查来检测癌症相关生物标记。 Plasma Focus 液体切片检查仅需标准抽血即可进行。它透过样本寻找肿瘤细胞释放到血液中的游离 DNA (cfDNA) 片段，这可能有助于深入了解对特定患者最有效的癌症治疗方法。

A liquid biopsy is a laboratory test done on a sample of blood, urine, or other body fluid to look for cancer cells from a tumor or small pieces of DNA, RNA, or other molecules released by tumor cells into a person's body fluids. Liquid biopsy allows multiple samples to be taken over time, which may help doctors understand what kind of genetic or molecular changes are taking place in a tumor. A liquid biopsy may be used to help find cancer at an early stage. It may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back.

It is composed of different biological matrices such as circulating tumor cells (CTCs), cell-free nucleic acids, exosomes or tumors "educated platelets." Recent technological and molecular advances, greatly facilitated by the use of microfluidics in many cases, have permitted large progress in both the ability to purify and analyze liquid biopsy components.

Market Dynamics: Drivers

Increasing prevalence of breast cancer

The demand for the breast cancer liquid biopsy market is driven by multiple factors. The rising prevalence of breast cancer propels the market growth.

Furthermore, the demand for treatment will be fueled by the increase in awareness among people and technological advancements. For instance, according to uicc.org, Breast cancer is the most diagnosed cancer among women worldwide and is the most diagnosed cancer in women in 157 countries, accounting for 1 in 4 cancer cases. It is the second most frequent cancer amongst both sexes and is the leading cause of death from cancer in women. With the estimated 2.3 million new cases of breast cancer in 2022, roughly one in every 9 cancers for both sexes diagnosed globally was breast cancer. In 2022, there were an estimated 669,418 deaths from breast cancer, with a disproportionate number of these deaths occurring in low-resource settings.

Moreover, according to breastcancer.org, About 66% of breast cancer cases are diagnosed at a localized stage before cancer has spread outside of the breast when it is easiest to treat. There are currently more than four million women with a history of breast cancer in the US.

Moreover, according to an article posted by WHO in February 2023, there are more than 2.3 million cases of breast cancer that occur each year, which makes it the most common cancer among adults. In 95% of countries, breast cancer is the first or second leading cause of female cancer deaths. Yet, survival from breast cancer is widely inequitable between and within countries nearly 80% of deaths from breast and cervical cancer occur in low- and middle-income countries.

Restraints

Factors such as high costs associated with liquid biopsy, the shortage of skilled professionals, and stringent regulatory requirements for the approval of new treatments are expected to hamper the market.

Market Segment Analysis

The global breast cancer liquid biopsy market is segmented based on product type, circulating biomarkers, application, end-user, and region.

The segment circulating tumor cells (CTCs) accounted for approximately 47.9% of the global breast cancer liquid biopsy market share

The circulating tumor cells segment is expected to hold the largest market share over the forecast period. In this segment, the technological advancements, and rising funds for private manufacturers for research work would drive this market.

Circulating tumor cells (CTCs) as a liquid biopsy have great potential in clinical applications and basic cancer research. Liquid biopsy, a minimally invasive technique, allows for the detection of cancer biomarkers directly from bodily fluids. Among these biomarkers, CTCs, cell-free DNA (cfDNA), and RNA provide a dynamic glimpse into the tumor's genetic landscape. This revolutionary approach offers promising avenues for early cancer detection, monitoring disease progression, and tailoring personalized treatment strategies.

CTCs are now recognized as crucial players in the metastatic process. Their detection and analysis have paved the way for the development of liquid biopsy techniques, offering a minimally invasive alternative to traditional tissue biopsies. This innovative approach has revolutionized our understanding of tumor dynamics, enabling real-time monitoring and providing insights into tumor heterogeneity, treatment response, and disease progression.

Market Geographical Analysis

North America accounted for approximately 42.8% of the global breast cancer liquid biopsy market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of breast cancer, and growing awareness among people, in this region, help to propel the market.

For instance, according to breastcancer.org, approximately 13% (about one in eight) of U.S. women will develop invasive breast cancer in the course of their life. In recent years, incidence rates have increased slightly by 0.5% per year. Breast cancer is still one of the leading causes of cancer-related death in U.S. women, second only to lung cancer. Breast cancer is the most commonly diagnosed cancer among U.S. women after skin cancers. Each year, about 30% of all newly diagnosed cancers in women are breast cancer. There are currently more than four million women with a history of breast cancer in the US.

Moreover in June 2023, Labcorp launched liquid biopsy to detect cancer-related biomarkers. The Plasma Focus liquid biopsy requires only a standard blood draw to run. It looks through the sample for bits of cell-free DNA (cfDNA) that are released by tumor cells into the bloodstream and that may offer insights into the cancer treatments that'll work most effectively for a specific patient.

Market Segmentation

By Product Type

Reagents & Kits

Instruments

By Circulating Biomarkers

Circulating Tumor Cells (CTCs)

Circulating Cell-free DNA (cfDNA)

Extracellular Vesicles (EVs)

Others

By Application

Early Screening

Treatment Selection

By End-User

Hospitals

Diagnostic Centers

Research and Educational Institutions

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the global breast cancer liquid biopsy market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, Agilent Technologies Inc., Merck KGaA, Cell Signaling Technology Inc., Medtronic, Bio-Rad Laboratories Inc., ExoDx, and Biocept Inc. among others.

Key Developments

On September 2023, nRichDX(R) launched its new RUO-labeled CTC enrichment kit that uniquely isolates Circulating Tumor Cells (CTCs) from up to 40mL of whole blood samples to help researchers advance liquid biopsy assay research and development.

Why Purchase the Report?

To visualize the global breast cancer liquid biopsy market segmentation based on product type, circulating biomarkers, application, end-user, and region, as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development

Excel data sheet with numerous data points of global breast cancer liquid biopsy market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global breast cancer liquid biopsy market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Circulating Biomarkers
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Prevalence of Breast Cancer
  - 4.1.1.2. Increasing Awareness Among People
  - 4.1.1.3. Technological Advancements
4.2. Restraints
- 4.2.1. High Costs Associated with Liquid Biopsy
- 4.2.2. Shortage of Skilled Professionals
- 4.2.3. Stringent Regulatory Requirements
4.3. Opportunity
4.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Reagents and Kits*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Instruments

7. By Circulating Biomarkers

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarkers
- 7.1.2. Market Attractiveness Index, By Circulating Biomarkers
7.2. Circulating Tumor Cells (CTCs)*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Circulating Cell-free DNA (cfDNA)
7.4. Extracellular Vesicles
7.5. Others

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Early Screening*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Treatment Selection

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic Centers
9.4. Research and Educational Institutions
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarkers
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. The U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarkers
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. UK
  - 10.3.7.3. France
  - 10.3.7.4. Italy
  - 10.3.7.5. Spain
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarkers
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulatory Biomarkers
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulatory Biomarkers
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. F. Hoffmann-La Roche Ltd. *
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Thermo Fisher Scientific Inc.
12.3. Abbott
12.4. Agilent Technologies Inc.
12.5. Merck KGaA
12.6. Cell Signaling Technology Inc.
12.7. Medtronic
12.8. Bio-Rad Laboratories Inc.
12.9. ExoDx
12.10. Biocept Inc. (*LIST NOT EXHAUSTIVE)